Black Triangle Drugs (▼) - An Outline

Abstract

Each drugs undergoes clinical trial phase before introducing into pharmaceutical market. Generally clinical trials involve a small number of patients who take the medicine for a short period. During this phase, patients are carefully selected and followed up very closely under controlled conditions. These initial trials will report only more common adverse drug effects. But the rare and long latency adverse drug effects can be reported only when the medicine is consumed by a large population [1]. In a real-life setting, a larger and more diverse group of patients will take the medicines. They may have co-morbidities and they may be taking other concomitant medicines also. Some less common or rare side effects may only occur once a medicine has been used for a long time or duration by many people. It is therefore vital that the safety of all medicines continues to be monitored while they are in commercial use. Information is continuously collected after the medicine is placed on the market to monitor real-life experiences with the product. The Commission on Human Medicines (CHM) and Medicines and Healthcare products Regulatory Agency (MHRA) encourage the reporting of all suspected reactions to newly introduced medicines to the market.